NASDAQ:FATE Fate Therapeutics Q2 2026 Earnings Report $2.53 +0.09 (+3.69%) Closing price 04:00 PM EasternExtended Trading$2.50 -0.03 (-1.19%) As of 05:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Fate Therapeutics EPS ResultsActual EPS-$0.25Consensus EPS -$0.25Beat/MissBeat by +$0.00One Year Ago EPSN/AFate Therapeutics Revenue ResultsActual Revenue$2.08 millionExpected Revenue$1.94 millionBeat/MissBeat by +$138.00 thousandYoY Revenue GrowthN/AFate Therapeutics Announcement DetailsQuarterQ2 2026Date8/13/2026TimeBefore Market OpensConference Call DateThursday, August 13, 2026Conference Call Time7:00AM ETUpcoming EarningsFate Therapeutics' Q3 2026 earnings is estimated for Thursday, October 29, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Fate Therapeutics Earnings HeadlinesFate Therapeutics To Present Off-The-Shelf CAR T Portfolio At ACR Convergence 2026September 16 at 5:48 PM | rttnews.comFate Therapeutics Announces Four ACR Convergence 2026 Abstracts Highlighting Off-the-Shelf CAR T-Cell Programs in Autoimmune DiseaseSeptember 16 at 7:10 AM | quiverquant.comQThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered separation packages to 8,500 workers, and Oracle is reportedly eliminating up to 30,000 positions. Goldman Sachs estimates 12,400 Americans are being financially displaced every single day. Analyst Porter Stansberry says the real driver runs deeper than AI - and two Nobel Prize winners have issued the same warning. He calls it the Final Displacement, and he's releasing a full investigation with specific companies to buy and sell before the next wave hits.September 17 at 1:00 AM | Porter & Company (Ad)Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026September 16 at 7:00 AM | globenewswire.comFate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Recommendation of "Hold" by AnalystsSeptember 14 at 2:44 AM | americanbankingnews.comFate Therapeutics, Inc.: Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR - West 2026 MeetingSeptember 9, 2026 | finanznachrichten.deSee More Fate Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Fate Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fate Therapeutics and other key companies, straight to your email. Email Address About Fate TherapeuticsFate Therapeutics (NASDAQ:FATE) is a clinical-stage biopharmaceutical company focused on developing cellular immunotherapies for cancer and autoimmune diseases. The company uses its induced pluripotent stem cell (iPSC) platform to produce potentially off-the-shelf immune-cell therapies designed to be manufactured at scale and administered to multiple patients. Its research and development programs include iPSC-derived natural killer (NK) cell and T-cell therapies. Notable candidates have included FT596, an iPSC-derived NK-cell therapy, and FT819, an iPSC-derived T-cell therapy targeting CD19. Fate has evaluated its investigational therapies in clinical studies for hematologic malignancies and has pursued additional applications in solid tumors and autoimmune disorders. The company does not have commercially approved products. Founded in 2007 and headquartered in San Diego, California, Fate Therapeutics conducts its research and clinical development activities primarily in the United States, with clinical studies potentially involving sites in other regions. Scott Wolchko serves as the company's president and chief executive officer.View Fate Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Aeluma’s Selloff Could Be Setting Up Its Next Big MoveCoreWeave’s Vera Rubin Lead Comes Down to Speed, Power, and ScaleMicron’s New 512GB Memory Module Deepens Its AI Infrastructure AdvantageHoliday Shopping Is Almost Here—And Target May Be Ready to Win BigCan ServisFirst Keep Delivering?Banc of California Bets on Short-Term Pain3 Luxury Consumer Brands to Watch in a Beaten-Down Sector Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
